

haematologica *the hematology journal*

author contribution form

Title	Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with <i>EBF1-PDGFRB</i> fusion.
First author	Etienne LENGLINE

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author(s) of this manuscript confirm(s) that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Specific contributions of each author are listed on page 2 of this document.

Responsible author(s):

author(s) responsible for the integrity of the work as a whole

Name: Emmanuelle CLAPPIER.....
Institute: Saint-Louis hospital, Paris.....
e-mail: emmanuelle.clappier@rdb.aphp.fr.....

Name:
Institute:
e-mail:

Author contributions (maximum 1 page):

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, collection of images, interpretation of data, preparation of the text, etc.)

EL and NB managed the patient, designed therapy and wrote the manuscript; KB provided MRD data; HD designed therapy; JS and EC analyzed the data and wrote the manuscript. All the authors approved the manuscript.